Want to see SE:ALZ full AI Analyst Report?

Alzinova AB (ALZ) Price & Analysis

2 Followers

ALZ Stock Chart & Stats

kr0.82

-kr0.14(-4.96%)

At close: Mar 06 4:00 PM EST

kr0.82

-kr0.14(-4.96%)

Day’s Range― - ―

52-Week Rangekr0.38 - kr2.28

Previous CloseN/A

Volume98.89K

Average Volume (3M)655.64K

Market Cap

kr100.31M

Enterprise Valuekr39.54M

Total Cash (Recent Filing)kr11.38M

Total Debt (Recent Filing)kr800.00K

Price to Earnings (P/E)―

Beta0.18

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.26

Shares Outstanding202,640,560

10 Day Avg. Volume664,473

30 Day Avg. Volume655,642

Financial Highlights & Ratios

PEG Ratio0.20

Price to Book (P/B)0.68

Price to Sales (P/S)0.00

P/FCF Ratio-2.10

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.32

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Balance Sheet StrengthVery low debt-to-equity (~0.7%) reduces solvency risk and gives management flexibility. For a clinical-stage biotech this structural conservatism supports continued R&D spending, negotiating power in partnerships and lower bankruptcy risk versus highly leveraged peers.

Focused Alzheimer’s Vaccine PipelineA concentrated R&D effort around a disease-modifying Alzheimer’s vaccine (ALZ-101) provides clear strategic focus. Success would create high clinical and licensing value; structurally, a single, well-articulated lead program simplifies partner diligence and resource allocation over the medium term.

Multiple Financing And Partnership PathwaysThe business model anticipates diverse funding sources—licensing, grants, equity raises and collaborations—which is durable for clinical-stage firms. Multiple legitimate capital pathways reduce single-source dependency and improve odds of securing non-dilutive or strategic funding to advance trials.

Bears Say

Revenue CollapseRevenue has effectively fallen to zero, indicating no commercialized products and no organic sales runway. Over months, lack of product revenue forces reliance on external financing or deals, weakening self-funding ability and increasing strategic pressure to secure partnerships or dilutive raises.

Sustained Negative Cash FlowLarge, persistent operating and free cash outflows create structural funding needs. Even with low debt, ongoing cash burn heightens dependence on capital markets or partners, raises dilution risk, and can constrain trial pacing or development choices if financing becomes harder or more expensive.

Persistent Losses And Negative ReturnsSizable recurring losses and negative ROE erode shareholder equity over time and limit reinvestment capacity. Structurally, until clinical validation or partnership monetization occurs, ongoing negative profitability increases dilution risk and weakens long-term value creation prospects.

ALZ FAQ

What was Alzinova AB’s price range in the past 12 months?

Alzinova AB lowest stock price was kr0.38 and its highest was kr2.28 in the past 12 months.

What is Alzinova AB’s market cap?

Alzinova AB’s market cap is kr100.31M.

When is Alzinova AB’s upcoming earnings report date?

Alzinova AB’s upcoming earnings report date is Aug 20, 2026 which is in 46 days.

How were Alzinova AB’s earnings last quarter?

Alzinova AB released its earnings results on May 13, 2026. The company reported -kr0.056 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.056.

Is Alzinova AB overvalued?

According to Wall Street analysts Alzinova AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Alzinova AB pay dividends?

Alzinova AB does not currently pay dividends.

What is Alzinova AB’s EPS estimate?

Alzinova AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Alzinova AB have?

Alzinova AB has 202,640,560 shares outstanding.

What happened to Alzinova AB’s price movement after its last earnings report?

Alzinova AB reported an EPS of -kr0.056 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.704%.

Which hedge fund is a major shareholder of Alzinova AB?

Currently, no hedge funds are holding shares in SE:ALZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Alzinova AB

Alzinova AB (publ) is a Swedish biotechnology company dedicated to advancing novel immunotherapies against Alzheimer's disease. Their primary investigational product, ALZ-101, is a vaccine specifically designed to target oligomers responsible for Alzheimer's. Additionally, they are developing ALZ-201, a monoclonal antibody aimed at neutralizing harmful amyloid-beta (Aß) oligomers. Established in 2011, the company's operations are headquartered in Mölndal, Sweden.